CSL’s $200 targets hinge on swift FY27 turnaround

CSL’s FY26 print looked brutal at first glance, but the result worked as a reset because the headline damage was overwhelmingly tied to items investors could strip out. The company reported a “statutory net loss after tax of US$2.6 billion” after “US$7.1 billion of pre-tax impairments and US$799 million of restructuring costs, most of it non-cash,” yet “underlying net profit after tax and amortisation fell just 2% to US$3.1 billion,” allowing interim chief Gordon Naylor to credibly frame the year as “a year of reset.”

That framing mattered because the market had already absorbed much of the bad news: CSL had “flagged around US$5 billion of impairments back in May and cut its guidance at the same time,” and “by August the market was ready to treat the write-downs as history.” Once management said FY27 revenue would be steady and “underlying net profit” would grow “approximately 5%” — versus consensus “closer to 2%” — investors quickly repriced the stock for a better next year rather than dwelling on the loss just reported.

The speed of that rerating shows how decisively expectations shifted after the reset. Shares “have risen as much as 90% from their June low,” after the stock “bottomed at $90.00 in June” and then “closed Wednesday at $171.21 before easing to $166.89 on Thursday,” leaving it near an “average 12-month target” of “$173.04” and underscoring that the market had already moved a long way toward pricing in the improved FY27 narrative.

What the market is really pricing is not a vague recovery story but a narrow execution path: brokers pushing CSL above $200 are assuming transformation savings arrive fast enough in FY27 to support earnings before the rerating runs too far ahead. That is why the savings bridge matters so much — CSL delivered “US$176 million of savings during FY26,” and management is now targeting “US$400 million of savings in FY27 and US$550 million by FY28,” with those near-term gains explicitly underpinning upgrades such as Jarden’s $207 target.

That optimism looks demanding because the starting point was still only modest underlying improvement, with FY26 “revenue… down 1% in constant currency” and “underlying NPATA fell 2% to US$3.1 billion,” even as immunoglobulin revenue rose 7% and savings were ahead of schedule. For $200-plus targets to hold, FY27 therefore has to deliver a specific operating mix: management’s roadmap points to mid-single-digit group growth, “immunoglobulin sales expected to climb at a mid-to-high single-digit clip,” and newer therapies scaling quickly enough to offset “Vifor revenue [to] fall roughly 25% in FY27” while Seqirus posts only low-single-digit growth.

In other words, the rerating only makes sense if Behring’s plasma recovery and the transformation program convert into profit growth quickly, not eventually, because savings are also being split between margin support and reinvestment. That is why transformation savings are a required part of the $200 thesis rather than a bonus: brokers are effectively betting that cost-out will flow into earnings fast enough, while still funding growth initiatives, to keep FY27’s guided mid-single-digit progress from looking too thin against a share price already discounting a cleaner recovery.